Replacing brentuximab vedotin with nivolumab in first-line treatment combined with the chemotherapy regimen AVD improved progression-free survival in pediatric patients with newly diagnosed, advanced-stage classic Hodgkin lymphoma (cHL), report the authors of a phase 3 clinical trial sponsored by SWOG Cancer Research Network and being presented Sunday, Dec. 10, by senior author Kara Kelly, MD, Chair of Pediatric Oncology at Roswell Park Comprehensive Cancer Center, during the 2023 annual meeting of the American Society of Hematology in San Diego, California.